Literature DB >> 19372800

Dynamic characteristics of HIV-1 reservoirs.

Hwijin Kim1, Alan S Perelson.   

Abstract

PURPOSE OF REVIEW: To examine kinetic issues related to the stability of the latent reservoir and the observation of low levels of viremia (< 50 copies/ml) in patients treated with highly active antiretroviral therapy. RECENT
FINDINGS: Once HIV-1 RNA becomes undetectable it is difficult to deduce the events occurring in HIV-infected individuals. Analyses of viral blips and genetic changes in HIV-1 DNA have, however, provided insights into ongoing viral replication and the stability of the latent reservoir.
SUMMARY: Under potent therapy, HIV-1 RNA decays in two phases and then becomes undetectable by clinical assay. Three possible scenarios are explored: the viral load stabilizes at a new steady state, or viral clearance remains more rapid than viral production and viral load declines either in a third exponential phase that might reflect the half-life of the latent reservoir, or in a decelerating manner reflecting heterogeneities in the cell populations making up the latent reservoir. A simple model shows that depending on the viral burst size it may be possible to sustain a low approximately steady level of viremia, say 10 copies/ml, for years without seriously depleting the latent reservoir.

Entities:  

Year:  2006        PMID: 19372800     DOI: 10.1097/01.COH.0000203836.08974.96

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  3 in total

Review 1.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

2.  Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  Math Biosci       Date:  2008-10-17       Impact factor: 2.144

3.  Viral and latent reservoir persistence in HIV-1-infected patients on therapy.

Authors:  Hwijin Kim; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2006-08-28       Impact factor: 4.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.